The blood-brain barrier (BBB) consists of specific physical barriers, enzymes and transporters, which together maintain the necessary extracellular environment of the central nervous system (CNS) . Here we demonstrate a direct role of pericytes at the BBB in vivo. Using a set of adult viable pericytedeficient mouse mutants we show that pericyte deficiency increases the permeability of the BBB to water and a range of low-molecularmass and high-molecular-mass tracers. The increased permeability occurs by endothelial transcytosis, a process that is rapidly arrested by the drug imatinib. Furthermore, we show that pericytes function at the BBB in at least two ways: by regulating BBB-specific gene expression patterns in endothelial cells, and by inducing polarization of astrocyte end-feet surrounding CNS blood vessels. Our results indicate a novel and critical role for pericytes in the integration of endothelial and astrocyte functions at the neurovascular unit, and in the regulation of the BBB.
.
The main physical barrier is found in the CNS endothelial cell, and depends on continuous complexes of tight junctions combined with reduced vesicular transport 2 . Other possible constituents of the BBB include extracellular matrix, astrocytes and pericytes 3 , but the relative contribution of these different components to the BBB remains largely unknown 1, 3 . Here we demonstrate a direct role of pericytes at the BBB in vivo. Using a set of adult viable pericytedeficient mouse mutants we show that pericyte deficiency increases the permeability of the BBB to water and a range of low-molecularmass and high-molecular-mass tracers. The increased permeability occurs by endothelial transcytosis, a process that is rapidly arrested by the drug imatinib. Furthermore, we show that pericytes function at the BBB in at least two ways: by regulating BBB-specific gene expression patterns in endothelial cells, and by inducing polarization of astrocyte end-feet surrounding CNS blood vessels. Our results indicate a novel and critical role for pericytes in the integration of endothelial and astrocyte functions at the neurovascular unit, and in the regulation of the BBB.
Platelet-derived growth factor (PDGF)-B/PDGF receptor-b (PDGFRb) signalling is necessary for pericyte recruitment during angiogenesis 4, 5 . Perinatal lethality precludes analysis of postnatal processes in Pdgfb or Pdgfrb null mice 6, 7 , but several other mouse mutants of this pathway are viable postnatally. Two such mutants were used here: PDGF-B retention motif knockouts (Pdgfb ret/ret ) where PDGF-B binding to heparan sulphate proteoglycans was disrupted 8 ; and mutants in which Pdgfb null alleles were complemented by one or two copies of a conditionally silent human PDGF-B transgene targeted to the Rosa26 locus and activated by endothelial Cre recombinase (hemizygous R26P 1/0 or homozygous R26P 1/1 mice; Supplementary Fig. 2a-d ). We quantified pericyte coverage in different regions of the CNS by CD13 or PDGFR-b staining (Fig. 1a, b, e and Supplementary Fig. 3 ). Pdgfb ret/ret , R26P
1/0 and R26P 1/1 mice displayed pericyte coverage corresponding to 26%, 40% and 72%, respectively, compared to controls (Fig. 1a, b) . Quantification of absolute numbers of mural cells (pericytes and vascular smooth muscle cells) using the transgenic reporter XLacZ4 9 confirmed low mural cell densities in Pdgfb ret/ret and R26P 1/0 mice, and close to normal levels in R26P 1/1 mice (Supplementary Fig. 3b-p) . We extended previous observations 4, 5, 10, 11 that reduced pericyte densities correlate with increased vessel diameter and reduced vessel density (Fig. 1c-e and Supplementary Fig. 4 ). Importantly, these phenotypes were almost completely normalized in R26P
1/1 mice (Fig. 1d , e and Supplementary Fig. 4a-c) . Increased water content in brains of Pdgfb ret/ret mice ( Fig. 1f) indicated impairment of the BBB. We tested the BBB integrity in the different mutants using a panel of tracers (Supplementary Table 1 ). The azo dye Evans blue 12 accumulated in mutant brain parenchyma in a timedependent fashion (Fig. 1i ) and in correlation with pericyte density: it was largest in Pdgfb ret/ret mice followed by R26P 1/0 and R26P
( Fig. 1g , h, j and Supplementary Fig. 5a-c) . Similarly, the fluorescent dye cadaverine Alexa Fluor-555 accumulated significantly in the brain parenchyma of Pdgfb ret/ret and R26P 1/0 mice ( Fig. 1j and Supplementary Fig. 5d, h, i) . Additionally, fluorescently labelled albumin, 70 kDa dextran and IgG passed the BBB in Pdgfb ret/ret and R26P 1/0 mice, but not in controls or in R26P 1/1 mice ( Fig. 1j and Supplementary Fig. 5e-g ). These experiments establish a close correlation between pericyte density and permeability across the BBB for a range of tracers of different molecular masses (Supplementary Table 1) .
Permeability in CNS vessels is impeded by continuous complexes of endothelial junctions 13, 14 . We studied such complexes in adult pericytedeficient mutants using markers for adherens (VE-cadherin) and tight (ZO-1 and claudin 5) junctions. Pdgfb ret/ret , R26P
1/0 and controls showed junctional marker expression at similar levels as judged by immunostaining and western blotting ( Supplementary Fig. 6a -c and data not shown). The junctional markers were distributed in a pattern consistent with continuous junction complexes in both mutants and controls; however, mutants displayed focally increased junctional width and undulation. These patterns were confirmed by transmission electron microscopy, which failed to reveal any apparent abnormalities in the ultrastructure of endothelial junctions, with the exception that longer and irregular stretches of endothelial overlap were commonly found in pericyte-deficient mutants ( Fig. 2c and Supplementary Fig. 6e ).
Because continuity, ultrastructure and marker expression were consistent with retained integrity of endothelial junctions in the absence of pericytes, we took advantage of the fixable nature of the fluorescent tracers to explore the route of extravasation in Pdgfb ret/ret and R26P
1/0 mice in more detail. Cadaverine Alexa Fluor-555 accumulated in endothelial cells and in the brain parenchyma in Pdgfb ret/ret and R26P 1/0 mice, but not in controls or in R26P 1/1 mice (Fig. 2a) . Extravasated cadaverine Alexa Fluor-555 localized mainly to neurons (Figs 2a and 3d and Supplementary Fig. 7a ). Similar patterns of distribution were observed for fluorescent albumin, IgG and 70 kDa dextran ( Fig. 2b and Supplementary Fig. 7b ). We also studied the distribution of horseradish peroxidase (HRP, 44 kDa) by transmission electron microscopy. We found increased uptake of HRP specifically in macrovesicular structures in the endothelium in Pdgfb ret/ret mice in comparison with controls (Fig. 2c, d and Supplementary Fig. 6d, e) . Pdgfb ret/ret microvessels also showed marked accumulation of HRP reactivity at the vascular basement membrane, without apparent colocalization with endothelial junctions (Fig. 2c, d and Supplementary  Fig. 6d, e) . Together, these observations indicate that macromolecular permeability across the BBB in pericyte-deficient vessels occurs through a transcytosis route. Pericyte deficiency was not associated with changes in the polarization or with signs of fenestration in the endothelial cells (Supplementary Figs 4d, 6d , e and 7c), features that characterize the BBB defects observed as a result of impaired Wnt/bcatenin signalling 15, 16 . The BBB breaks open in conjunction with stroke, leading to lifethreatening CNS oedema. A recent study demonstrated that the tyrosine kinase inhibitor imatinib counteracts oedema in experimental 
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stroke induced in mice 17 . We found that imatinib treatment quickly and dose-dependently reversed brain parenchymal accumulation of all tested tracers in pericyte-deficient mice ( Fig. 3 and Supplementary  Fig. 8 ). In contrast, accumulation and punctuate distribution of fluorescent dextran and IgG in the endothelial cells was enhanced ( Fig. 3e and Supplementary Fig. 8b, d, e) . This indicates that imatinib inhibits the release of tracer from endothelial cells into the brain parenchyma, consistent with an effect on a late step in the endothelial transcytosis process. Notably, imatinib treatment did not normalize pericyte abundance, vessel diameter, density, or the convoluted appearance of endothelial junctions ( Fig. 3d and Supplementary Fig. 9 ).
To address whether pericytes regulate brain-specific endothelial differentiation we used microarrays to assess the expression of known BBB markers 3 in microvascular fragments isolated from adult pericyte-deficient mutants and controls. Such fragments mostly consist of endothelial cells 18 , but also include pericytes (when present) and astrocyte end-feet. We used previously obtained array data on embryonic brain microvascular fragments, isolated kidney glomeruli and whole brain for comparison [18] [19] [20] . These analyses show that most BBB markers are unaffected by pericyte deficiency at the mRNA level (Fig. 4a, b and Supplementary Table 2 ). Two known BBB markers for which antibodies were available were assessed at the level of protein expression: Glut1 (predicted to be unaffected by pericyte deficiency) and transferrin receptor (CD71) (predicted to be downregulated in the pericyte-deficient state). In agreement with the gene expression data, we found that Glut1 protein was uniformly expressed in brain endothelial cells irrespective of the degree of pericyte coverage (Figs 2-4 and Supplementary Fig. 10 ), whereas CD71 expression was downregulated in the endothelium lacking pericyte contact ( Supplementary Fig. 10 ). Together, these results indicate that pericytes exert a discrete influence on the endothelial BBB-specific gene and protein expression profile.
Astrocytes attach to blood vessels through cap-like cytoplastic processes-end-feet-carrying specific channels and transporters, for example, aquaporin 4 (Aqp4) and Kir4.1, which are targeted to astrocyte end-feet to control water and ion homeostasis at the vesselneuron interface 3 . Little is known about how contacts between blood vessels and astrocyte end-feet are established and maintained 21 . Our gene array data indicated downregulation of several astrocyte markers in pericyte-deficient brain microvascular fragments (Supplementary  Table 2 and data not shown). We therefore asked if pericytes, which are partially sandwiched between the endothelial cells and the astrocyte end-feet, might affect astrocytes, and, specifically, if pericyte deficiency leads to changes in astrocyte end-foot distribution or polarization. Three markers for the polarized astrocyte end-foot, Aqp4, a-syntrophin and laminin a2 chain (Lama2), all provided uniform labelling of microvessel abluminal surfaces in control brains, consistent with a polarized expression of these markers (Fig. 4c-e and Supplementary Fig. 11 ). However, in pericyte-deficient mutants, the vascular staining for these markers was weaker than in controls, and the Aqp4 staining was also re-distributed to other regions of the astrocytes, indicating abnormal polarization of the astrocyte end-feet ( Supplementary Fig. 11 ). Interestingly, we found that pericytes that were detached from the endothelial cells showed intense lining with Aqp4 and a-syntrophin immunostaining (Fig. 4d and data not shown) . This indicates that pericytes express cues that mediate attachment of astrocyte end-feet. The strong reduction in deposition of the astrocyte-derived basement membrane component Lama2 (Fig. 4e) prompted us to study the expression of a range of other vascular basement membrane components. These analyses failed to show any significant changes in the deposition of endothelium-derived basement membrane proteins laminin a4, laminin a5, nidogen and perlecan in pericyte-deficient vessels ( Supplementary Fig. 12 ).
BBB properties are not intrinsic to CNS endothelial cells, but are induced when the cells are in contact with astrocytes in vitro and in vivo [22] [23] [24] . Recent evidence also suggests a role for neuronal precursors and Wnt signalling in BBB induction in vivo 15, 16, 25 . A role for pericytes 
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in endothelial barrier formation has been suggested based on in vitro co-culture experiments 26, 27 , but evidence for any specific role of pericytes in BBB formation has so far been lacking. Here we provide evidence for an in vivo role of pericytes in regulating the mammalian BBB (schematically illustrated in Supplementary Fig. 1 ). The increased endothelial transcytosis that occurs as a result of brain pericyte deficiency in the mouse mutants is compatible with a normal lifespan of the mouse mutants, in spite of the fact that this increase results in oedema and extravasation of plasma proteins in the brain. This is probably tolerated because leakage is slow, allowing the brain to adapt and compensate for any resulting changes in the interstitial environment. Viable pericyte-deficient animal models should therefore be useful in further studies of the putative functional consequences of BBB impairments for higher and integrated neuronal functions, learning and behaviour, and for the progression of brain diseases. Notably, we have demonstrated that the pericyte-deficient state makes the BBB permeable to immunoglobulins. Further elucidation of the molecular mechanisms that trigger opening and closure of this route across the BBB should therefore be of pharmaceutical significance. Generation of Rosa26 hPDGF-B mice. A full-length human PDGF-B cDNA sequence preceded by a splice acceptor site and a loxP-site-flanked transcription stop cassette was cloned into a vector designed for homologous recombination into the ubiquitously expressed ROSA26 locus 30 ( Supplementary Fig. 2a ). Genetargeted mice were generated from the ES cells by standard methods. A detailed description is provided in Methods. Intravenous injection of tracers and detection of injected tracers. The following tracers were used: Evans blue (Sigma Aldrich), lysine-fixable cadaverine conjugated to Alexa Fluor-555 (Invitrogen), bovine serum albumin conjugated to Alexa Fluor-555 (Invitrogen), lysine-fixable 70 kDa dextran conjugated to tetramethylrhodamine (TMR) (Invitrogen), and goat anti-human IgG conjugated to DyLight 549 (Jackson Immunoresearch Laboratories). Evans blue in the brain was quantified by spectrophotometry as described 17 . Detailed information about the quantification of cadaverine-Alexa Fluor-555 and DyLight-549 conjugated goat anti-human IgG in the brain is given in Methods. When indicated, animals were treated with three or four doses of imatinib (150 mg kg
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) twice per day before tracer injections. Statistical analysis. Statistical significance was determined by using unpaired two-tailed or one-tailed Student's t-test (GraphPad Prism5). Differences were considered significant with a P value less than 0.05. Quantified data are presented as mean 6 s.e.m. Tables 2 and 3 for gene identifiers and further information on methodology). c, d, Astrocyte endfeet (red) localize to microvessels (green) in controls but also to structures bridging adjacent vessels in Pdgfb ret/ret and R26P 1/0 mice (arrowheads in c) that were identified as detached PDGFR-b positive pericytes (d, arrowheads). Arrows in c point to diffuse Aqp4 staining (red) in pericyte-deficient mice not associated with vessels (see also Supplementary Fig. 11a) . Pdclxn, podocalyxin. Generation of Rosa26 hPDGF-B mice. A DNA cassette consisting of a fulllength human PDGF-B cDNA sequence preceded by a splice acceptor site and a loxP-site-flanked transcription stop cassette was cloned into a vector designed for homologous recombination into the ubiquitously expressed ROSA26 locus 30 ( Supplementary Fig. 2a ). The targeting vector was verified by sequencing and electroporated into endothelial cells. Positive clones were identified by PCR and confirmed by Southern blot hybridization as described 30 . Gene-targeted mice were generated from the ES cells by standard methods. Animal genotyping was done by PCR. The following PCR primers were used: R26F2, 59-AAAGTCGCT CTGAGTTGTTAT-39; R26SR, 59-CCCACTGGAAAGACCGCGAAGAGT-39; R523, 59-GGAGCGGGAGAAATGGATATG-39 generated a 250-bp PCR fragment from the mutant allele and a 500-bp fragment from the wild-type allele. Expression of hPDGF-B was activated in endothelial cells by crossing with Tie2Cre transgenes (Supplementary Fig. 2b) . Quantification of vessel diameter, density and pericyte coverage. Quantification of vessel pericyte coverage was performed on 50 mm vibratome brain sections. Four corresponding areas in three animals of each genotype were analysed at 3-5 months of age. Blood vessels were visualized by collagen IV and pericytes by CD13 or PDGFR-b immunostainings. 14-16-mm-thick z-stacks were captured using an LSM Meta 510 microscope (Carl Zeiss AG). Quantification of pericyte numbers, vessel length and diameter was performed using Volocity software (Improvision, a PerkinElmer Company). Antibodies and immunohistochemistry. The following primary antibodies were used: rabbit anti-rat aquaporin 4 (AB3068, Chemicon); rat anti-mouse CD13 (558744, BD PharMingen); rabbit anti-mouse collagen IV (2150-1470, AbD Serotec); rabbit anti-Glut1 (07-1401, Millipore); rat anti-mouse PDGFR-b (14-1402, eBioscience); goat anti-mouse podocalyxin (AF1556, R&D Systems). Secondary antibodies (goat anti-rat, goat anti-rabbit, donkey anti-goat) conjugated with Alexa Fluor dyes were obtained from Invitrogen. For immunostainings in which two primary rabbit antibodies were used, one was directly labelled using the Zenon rabbit IgG labelling kit (Invitrogen). Immunohistochemistry was performed on 50 or 100 mm brain coronal vibratome sections. Specimens were analysed using an LSM 510 META (Carl Zeiss AG) microscope. Image processing was done using Volocity 64 (Improvision), Adobe Photoshop CS3, and Adobe Illustrator CS3 (Adobe Systems). All immunohistochemistry images presented are three-dimensional reconstructions of z-stacks. Intravenous injection of tracers and detection of injected tracers. Tracers were injected intravenously into the tail vein in adult (2-8 months) mice. The following tracers were used: Evans blue (Sigma Aldrich), lysine-fixable cadaverine conjugated to Alexa Fluor-555 (Invitrogen), bovine serum albumin conjugated to Alexa Fluor-555 (Invitrogen), lysine-fixable 70 kDa dextran conjugated to tetramethylrhodamine (Invitrogen), and goat anti-human IgG conjugated to DyLight 549 (Jackson Immunoresearch Laboratories). More detailed descriptions of the tracer experiments are given in the Supplementary Methods. Images of dissected brains were captured using a stereomicroscope (SteREO Lumar.V12, equipped with HBO 100 lamp and a Filter Set Lumar 43 HE; Carl Zeiss AG) equipped with an AxioCam HRc (Carl Zeiss AG) camera. Evans blue in the brain was quantified by spectrophotometry as described 17 . For quantification of cadaverine-Alexa Fluor-555 and DyLight-549 conjugated goat anti-human IgG in the brain, anaesthetized animals were perfused for 5 min with Hanks' balanced salt solution (HBSS), brains and kidneys removed and homogenized in 1% Triton X-100 in PBS, pH 7.2. Brain and kidney lysates were centrifuged at 16,000 r.p.m. for 20 min and the relative fluorescence of the supernatant was measured on a fluorometer POLARstar Omega (BMG Labtech) (ex/em 544/590 nm). For in situ detection of fluorophoreconjugated tracers, anaesthetized animals were perfused for 1-2 min with HBSS, followed by 5 min perfusion with 4% PFA in PBS, pH 7.2. Brains were removed and the tissue was post-fixed in 4% PFA in PBS, pH 7.2 at 4 uC for 5-6 h. 50-mm-thick coronal brain sections were immunostained with anti-Glut1 antibody. Samples were analysed by confocal microscopy (LSM 510 META, Carl Zeiss AG). When indicated, animals were treated with three or four doses of imatinib (150 mg kg 21 ) twice per day before tracer injections. Transmission electron microscopy. Two-month-old mice were injected intravenously with horseradish peroxidase Type II (HRP) (100 mg ml 21 in PBS, 10 mg per 20 g) (Sigma Aldrich). After 2 h, animals were anaesthetized and perfused with 2.5% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.2. HRP-diaminobenzidine cytochemistry was performed on brain vibratome slices according to ref. 31 with minor modifications. After osmication and en bloc uranyl acetate treatment, tissue blocks were dehydrated and embedded in epoxy resin. Sections were cut with a diamond knife on a Leica EM UC7 ultramicrotome (Leica Microsystems) at 60 nm thickness setting and were examined without additional contrasting in a LEO 912AB energy-filtered transmission electron microscope (Carl Zeiss SMT AG). Digital images were captured with a MegaView III camera (Olympus SiS). Brain water content determination. Animals were anaesthetized and perfused with HBSS for 5 min via the left ventricle of the heart. Brains were removed and weighed for wet weight. Tissue was dried at 62 uC for 6 days and weighed again for dry weight. Purification of microvasculature and microarray analysis. Purification of microvasculature and RNA isolation was performed as described 20 . Four RNA samples of each genotype were individually hybridized to Affymetrix GeneChip Mouse Genome 430 2.0 microarrays. Publicly available Affymetrix raw data files concerning wild-type adult whole brain 32 , isolated wild-type adult glomeruli 20 , and wild-type embryonic and adult brain microvascular fragments 19 were downloaded and treated in the same manner as data generated in this study. Array data was processed using the Affy and gcrma packages in the Bioconductor project (http:// www.bioconductor.org). A Student's t-test was used to evaluate differential expression. The false discovery rate method was used to perform multiple test correction for P values 33 . The log 2 change was calculated as the log 2 of the average expression difference between sample groups. A detailed description of the samples used in different comparisons is given in Supplementary Table 3 . Statistical analysis. Statistical significance was determined by using unpaired two-tailed or one-tailed Student's t-test (GraphPad Prism5). Differences were considered significant with a P value less than 0.05. Quantified data are presented as mean 6 s.e.m. 
